Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease
Open Access
- 7 September 2012
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 19 (1) , 82-88
Abstract
Summary: Von Willebrand disease (VWD) is an inherited bleeding disorder caused by the quantitative or qualitative deficiency of von Willebrand factor (VWF). Replacement therapy with plasma‐derived VWF/factor VIII (FVIII) concentrates is required in patients unresponsive to desmopressin. To assess the efficacy, safety and ease of use of a new, volume‐reduced (VR) formulation of VWF/FVIII concentrate Haemate® P in patients requiring treatment for bleeding or prophylaxis for recurrent bleeding or for invasive procedures. Pharmacoeconomic variables were also recorded. Data were analysed using descriptive statistics. This was a multicentre, prospective, observational study. Consecutively enrolled patients received Haemate® P VR according to their needs, and were followed for 24 months. Of the 121 patients enrolled, 25.6% had type 3 VWD and more than 40% had severe disease. All patients were followed for 2 years, for a total of 521 visits. On‐demand treatment was given to 61.9% of patients, secondary long‐term prophylaxis to 25.6% and prophylaxis for surgery, dental or invasive procedures to 45.5%. The response to treatment was rated as good to excellent in >93–99% of interventions. The new formulation was well tolerated by all patients with no report of drug‐related adverse events. The switch to volume‐reduced Haemate® P was easy to perform and infusion duration was decreased twofold compared with the previous formulation. Volume‐reduced Haemate® P was at least as effective and well‐tolerated as the previous formulation.Keywords
This publication has 24 references indexed in Scilit:
- Learning intravenous infusion in haemophilia: experience from the NetherlandsHaemophilia, 2012
- Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgeryThrombosis and Haemostasis, 2011
- Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand diseaseThrombosis and Haemostasis, 2011
- Health‐related quality of life among adult patients with moderate and severe von Willebrand diseaseJournal of Thrombosis and Haemostasis, 2010
- Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE® in patients with von Willebrand’s disease: a prospective multi‐centre studyHaemophilia, 2010
- Prophylaxis in von Willebrand diseaseHaemophilia, 2008
- Haemate®P von Willebrand factor/factor VIII concentrate: 25 years of clinical experienceHaemophilia, 2008
- European principles of haemophilia careHaemophilia, 2008
- von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgeryJournal of Thrombosis and Haemostasis, 2007
- Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate‐P®): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapyHaemophilia, 2003